Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies

Table 3 Description of the patients fulfilling only ACR criteria or only AECG criteria

Patient	Sex	Age (years)	Duration (years)^a	Eye^b	Mouth^c	Arthritis^d	Lung^e	Neuro^f	Parotid^g	UWSF^h	Schirmerⁱ	OSS^j	Chisholm^k	ANA	Anti-SSA^l	Anti-SSB^l	RF (n < 0.2)	ACPA (n < 20)	IgG (mg/l)	Clinical^m
Detailed characteristics of the eight patients fulfilling only ACR criteria
1	F	25	0	1	0	0	0	0	0	0.35	8	3	1	160	146	46	0.14	9	9.2	SS
2	F	63	1	1	1	0	0	0	0	0.4	30	3	4	1,280	0	0	0	0	5.8	SS
3	F	34	1	1	0	1	0	0	0	0.2	20	4	4	1,280	174	0	0.5	250	16.2	RA
4	F	59	5	0	1	0	0	0	1	0.4	10	1	3	640	140	80	0.9	7	13.4	SS
5	F	61	5	1	1	0	0	0	0	0.5	8	3	3	0	0	0	0	0	12.1	Sicca
6	F	47	4	1	1	0	0	0	0	0.2	30	3	3	1,280	0	0	0	0	16.5	UCTD
7	F	57	1	1	1	1	0	1	0	0.5	30	4	4	160	0	0	0.52	250	12.7	RA
8	F	27	6	0	1	0	1	0	0	0.25	30	0	3	1,280	100	0	0.81	15	18.9	SLE
Detailed characteristics of the 15 patients fulfilling only AECG criteria
1	F	67	1	1	1	0	0	0	0	0.005	5	2	3	160	0	0	0	0	11.7	SS
2	F	45	1	1	1	0	0	0	0	0.001	5	2	2	640	154	0	0.05	0	13	SS
3	F	75	0	1	1	0	0	0	0	0.2	0	2	3	0	0	0	0.34	0	9.3	SS
4	F	56	1	1	1	0	0	0	0	0.005	25	2	2	1,280	24	152	0	0	9.9	SS
5	F	50	13	1	1	0	0	1	1	0.1	20	0	4	160	0	0	0	0	9.1	SS
6	F	69	6	1	1	0	0	0	0	0.25	5	1	4	1,280	0	0	0	0	10.3	SS
7	F	66	1	1	1	1	0	0	0	0.486	5	2	3	320	0	0	0	0	7	SS
8	F	55	7	1	1	0	1	0	0	0.02	15	2	4	160	0	0	0	0	7.1	SS
9	F	43	3	1	1	0	0	0	0	0.15	5	1	1	640	85	0	0	0	12.6	SS
10	F	78	10	1	1	0	0	0	0	0.05	7	2	3	160	0	0	0	0	9.7	SS
11	M	64	2	1	1	0	1	0	0	0.2	0	0	4	320	0	0	0	28	22.6	SS
12	F	60	8	1	1	0	0	1	1	0.05	5	2	3	640	9	32	0	72	8.43	SS
13	F	58	2	1	1	0	0	0	0	0.04	4	0	3	0	0	0	0	0	8.33	SS
14	F	43	10	0	1	0	0	0	0	0.06	0	1	2	320	40	0	0	0	10	SS
15	F	50	1	1	1	0	0	0	0	0.05	15	1	3	0	0	0	0	0	9.7	SS

ACPA, anti-citrullinated peptide antibodies; ACR, American College of Rheumatology; AECG, American–European Consensus Group; ANA, antinuclear antibody; F, female; IgG, serum level of immunoglobulin G; M, male; OSS, ocular staining score; SS, Sjögren’s syndrome. RA, rheumatoid arthritis; RF, rheumatoid factor; sicca, idiopathic sicca syndrome; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue disease; UWSF, unstimulated whole salivary flow. ^aDuration of the symptoms. ^bXerophthalmia (0, absent; 1, present). ^cXerostomia (0, absent; 1, present). ^dPresence of swollen and tender joints on the day of examination. ^eIncludes the presence of chronic dry cough or computed tomography-proven interstitial lung disease. ^fPatient with objective peripheral neuropathy. ^gPresence or history of parotidomegaly. ^hAbnormal if ≤0.1 ml/minute. ⁱSchirmer’s test abnormal if ≤ 5 mm/5 minutes. ^jAbnormal if ≥ 3. ^kChisholm’s grading of the lymphocytic infiltration on minor salivary gland biopsy (grades 3 and 4 correspond to a focus score ≥1 focus of more than 50 lymphocytes/4 mm²). ^lAnti-SSA and anti-SSB antibodies (n < 40). ^mDiagnosis made by the physician, without reference to specific classification criteria.

ISSN: 1478-6362